Clinical trial to investigate causes of diabetes, obesity in individuals with spinal cord injury and potential mitigatory effects of semaglutide
<p>A first-of-its-kind investigation into the mechanisms behind diabetes and obesity in people with spinal cord injury and the antidiabetic and anti-obesity effects of semaglutide was recently approved for $3 million in National Institutes of Health funding. “This is one population in which they are susceptible to be more obese and having worse diabetes risk and […]</p>